BMT Tandem "Scientific" Meeting
Seaport Ballroom ABC (Manchester Grand Hyatt)
Chairs:
Ginna G. Laport, MD
and
Leo Luznik, MD
Disclosures:
G. G. Laport,
Nothing To Disclose
L. Luznik,
Nothing To Disclose
Risk Stratification of Outcomes Among Patients with Adult T-Cell Leukemia/Lymphoma Receiving Allogeneic Hematopoietic Cell Transplantation: A Retrospective Analysis of the JSHCT ATL Working Group
Makoto Yoshimitsu, MD, PhD, Kagoshima University Graduate School of Medical and Dental Sciences;
Ryuji Tanosaki, MD, National Cancer Center Hospital;
Koji Kato, MD, PhD, Kyushu University Graduate School of Medical Science;
Takashi Ishida, MD, PhD, Nagoya City University Graduate School of Medical Sciences;
Ilseung Choi, MD, National Kyushu Cancer Center;
Takahiro Fukuda, MD, PhD, National Cancer Center Hospital;
Yoshifusa Takatsuka, MD, Imamura Bun-in Hospital;
Tetsuya Eto, MD, PhD, Hamanomachi Hospital;
Naoyuki Uchida, MD, PhD, Toranomon Hospital;
Yukiyoshi Moriuchi, MD, Sasebo City General Hospital;
Tokiko Nagamura-Inoue, MD, PhD, The Institute of Medical Science, The University of Tokyo;
Shin-Ichiro Mori, MD, St Luke's International Hospital;
Hisashi Sakamaki, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital;
Yoshiko Atsuta, MD, PhD, Nagoya University Graduate School of Medicine;
Atae Utsunomiya, M.D., Ph.D., Imamura Bun-in Hospital
Cytogenetics Does Not Influence Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia
Ibrahim Aldoss, City of Hope Medical Center;
Ni-Chun Tsai, MS, MPH, City of Hope;
Marilyn L Slovak, Palo Verde Laboratory/Sonora Quest Laboratoris;
Joycelynne Palmer, PhD, City of Hope;
Stephen J. Forman, City of Hope Medical Center;
Vinod Pullarkat, MD, City of Hope Medical Center
Allogeneic Stem Cell Transplantation (Allo-SCT) for the Treatment of T-Cell Acute Lymphoblastic Leukemia (T-ALL); Evaluation of Minimal Residual Disease and Prognostic Factors at the MD Anderson Cancer Center (MDACC)
Jonathan E Brammer, MD, The University of Texas MD Anderson Cancer Center;
Rima Saliba, PhD, The University of Texas MD Anderson Cancer Center;
Hagop Kantarjian, M.D. Anderson Cancer Center;
Deborah Thomas, MD, MD Anderson Cancer Center;
Jeffrey L Jorgensen, MD, The University of Texas MD Anderson Cancer Center;
Sameh Gaballa, MD, The University of Texas MD Anderson Cancer Center;
Celina Ledesma, BS, University of Texas, MD Anderson Cancer Center;
Uday R. Popat, MD, UT MD Anderson Cancer Center;
Elizabeth J. Shpall, MD, UT MD Anderson Cancer Center;
Richard E. Champlin, MD, The University of Texas MD Anderson Cancer Center;
Chitra Hosing, MD, The University of Texas MD Anderson Cancer Center;
Partow Kebriaei, MD, The University of Texas MD Anderson Cancer Center
Allogeneic Hematopoietic Cell Transplantation (HCT) Yields Lower Relapse Rates but No Overall Survival Benefit for Adults with Acute Lymphoblastic Leukemia (ALL) in First Minimal Residual Disease (MRD)-Negative Remission
Ryan D. Cassaday, MD, University of Washington;
D. Alan Potts, University of Washington School of Medicine;
Philip A. Stevenson, Fred Hutchinson Cancer Research Center (FHCRC);
Merav Bar, MD, Fred Hutchinson Cancer Research Center;
George Georges, MD, Fred Hutchinson Cancer Research Center;
Andrei R. Shustov, MD, Fred Hutchinson Cancer Research Center (FHCRC);
Mohamed L. Sorror, MD, MSc, Fred Hutchinson Cancer Research Center;
Brent L. Wood, MD, University of Washington;
Colleen Delaney, MD, MSc, Fred Hutchinson Cancer Research Center;
Kristine C. Doney, MD, Fred Hutchinson Cancer Rsrch Ctr;
Rainer F. Storb, MD, University of Washington;
Brenda M. Sandmaier, MD, Fred Hutchinson Cancer Research Center
Minimal Residual Disease By PCR Testing Is a Significant Predictor of Disease Relapse in Patients with FLT3 Positive AML after Hematopoietic Stem Cell Transplantation
Sameh Gaballa, MD, The University of Texas MD Anderson Cancer Center;
Rima Saliba, PhD, The University of Texas MD Anderson Cancer Center;
Betul Oran, MD, The University of Texas MD Anderson Cancer Center;
Jonathan E Brammer, MD, The University of Texas MD Anderson Cancer Center;
Julianne Chen, BS, The University of Texas MD Anderson Cancer Center;
Gabriela Rondon, MD, The University of Texas MD Anderson Cancer Center;
Amin Alousi, MD, UT MD Anderson Cancer Center;
Partow Kebriaei, MD, The University of Texas MD Anderson Cancer Center;
Uday R. Popat, MD, UT MD Anderson Cancer Center;
Borje S. Andersson, MD, PhD, The University of Texas MD Anderson Cancer Center;
Elizabeth J. Shpall, MD, UT MD Anderson Cancer Center;
Elias Jabbour, MD, The University of Texas MD Anderson Cancer Center;
Naval Daver, MD, The University of Texas MD Anderson Cancer Center;
Michael Andreeff, The University of Texas MD Anderson Cancer Center;
Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center;
Jorge Cortes, MD, The University of Texas MD Anderson Cancer Center;
Richard E. Champlin, MD, The University of Texas MD Anderson Cancer Center;
Stefan O. Ciurea, MD, The University of Texas MD Anderson Cancer Center
![[Visit Client Website]](images/banner.gif)